

Miltenyi Biotec inaugurates India's first cell and gene therapy CoE in Hyderabad

24 February 2025 | News

Fostering next-generation therapies and contributing to India's growing prominence in the global biotech landscape



Miltenyi Biotec, a global leader in cell and gene therapy (CGT) solutions, has launched India's first-ever dedicated cell & gene therapy centre-of-excellence (CoE) in Hyderabad. With this launch, Miltenyi Biotec reinforces its commitment to India. It also furthers the vision of the company to advance cutting-edge biotechnology and foster innovation in India's rapidly growing life sciences sector.

Spanning 1,800 sqm in Genome Valley, India's leading life sciences hub, MITC (Miltenyi innovation and technology centre) is designed to advance cell and gene therapy development.

It will foster innovation by integrating expertise, best practices, and cutting-edge technologies to combat diseases, including cancer. The facility features a showroom with advanced MACS instruments, a CliniMACS Prodigy platform for therapy development and manufacturing, and interactive training opportunities. It will serve as a collaborative hub, hosting seminars and workshops in immunology, stem cell biology, cancer, and other key areas.

MITC was inaugurated by Jayesh Ranjan, Special Chief Secretary for the Information Technology, Electronics & Communications (ITE&C), and Industries & Commerce Departments of the Government of Telangana and Dr Kathrin Misera-Lang, Consul General (interim) of the Federal Republic of Germany to the Republic of India, Chennai, along with other dignitaries.

D Sridhar Babu, IT and Industries Minister of Telangana emphasised, “This facility strengthens our healthcare ecosystem and supports our vision of making Telangana a global leader in advanced biotechnology and healthcare solutions, particularly in cell and gene therapies.”

Dr Boris Stoffel, Chief Commercial Officer, Member of the Board, Miltenyi Biotec B.V. & Co. KG, added, “MITC will drive advancements in biomedical research, supporting the scientific and medical community in developing new therapies for diseases with limited treatment options. It will enable close collaboration with researchers, physicians and industry providing them with the tools and expertise needed to deliver transformative therapies to patients.”